New Breast Cancer Treatments: Latest Advances and How to Access Them?

Breast cancer is one of the complex cancers. It is most commonly found in women worldwide. It develops in the breast tissue, typically in the ducts or lobules. It may spread to lymph nodes or other organs in case not detected and treated early. Treatment decisions depend on the cancer’s subtype, size, stage, and molecular profile.

Major Subtypes of Breast Cancer:

• Hormone Receptor-Positive (HR+) / HER2-Negative

•  HER2-Positive Breast Cancer

•  Triple-Negative Breast Cancer (TNBC)

• BRCA-Mutated Breast Cancer

• Metastatic Breast Cancer (mBC)

New developments in the medical field, such as the targeted therapies and treatments using Antibodies together with Drug Conjugates, immunotherapy, and many more, have made treating breast cancer easier, giving hope to the patients.

Standard Treatments for Breast Cancer:

Before exploring newly approved therapeutic drugs, it’s important to understand standard care options typically recommended based on stage and molecular subtype:

• Surgery – Performing a lumpectomy, which is the removal of lumps of tissue, or a mastectomy, which is the removal of both breast tissues of the patient’s body.
• Radiation Therapy – Killing remaining leaves or cancer cells using beams of high-intensity energies.
• Chemotherapy – Medications that are used to kill or limit cancerous cells.
• Hormonal Therapy – Slows or blocks HR+ cancer by inhibiting hormone receptors
• Targeted Therapy – Stopping the growth of cancer from the root on a molecular level.
• Immunotherapy – Boost the immune system of patients to help them fight against cancer cells.

• Newly Approved Medicines for Breast Cancer:
  Here are some of the most promising, recently approved therapeutic drugs. These help in improving outcomes for various types of breast cancer:
• Trodelvy (sacituzumab govitecan-hziy):
  Type: Antibody-Drug Conjugate (ADC)
  Use: For Triple-Negative Breast Cancer (TNBC) after ≥2 prior treatments
  Region: US, EU, UK
  Mechanism: Targets Trop-2, delivering SN-38 (a topoisomerase inhibitor) directly to unhealthy cells to limit systemic toxicity
• Enhertu (trastuzumab deruxtecan):
  Type: Antibody-Drug Conjugate (ADC)
  Use: For HER2-positive and HER2-low metastatic breast cancer
  Region: US, EU, Japan
  Mechanism: Targets HER2 protein and releases a topoisomerase I inhibitor to kill unhealthy cells with high precision
• Verzenio (abemaciclib):
  Type: CDK4/6 Inhibitor
  Use: HR+/HER2- early and metastatic breast cancer, in combination with endocrine therapy
  Region: US, EU, India
  Mechanism: Inhibits CDK4/6, halting cell cycle progression and slowing tumor growth
• Ibrance (palbociclib):
  Type: CDK4/6 Inhibitor
  Use: HR+/HER2- metastatic breast cancer with letrozole or fulvestrant
  Region: US, EU, India
  Mechanism: Blocks CDK4/6 enzymes, preventing cancer cell proliferation
• Kisqali (ribociclib):
  Type: CDK4/6 Inhibitor
  Use: HR+/HER2- advanced or metastatic breast cancer, with hormone therapy
  Region: US, EU
  Mechanism: Inhibits cyclin-dependent kinases 4 and 6, disrupting cancer cell division
• Piqray (alpelisib) + Fulvestrant:
  Type: PI3K Inhibitor (with ER degrader)
  Use: HR+/HER2- metastatic breast cancer with PIK3CA mutation
  Region: US, EU
  Mechanism: Inhibits PI3Kα isoform to block signaling that drives tumor cell growth
• Lynparza (olaparib):
  Type: PARP Inhibitor
  Use: HER2-negative metastatic breast cancer with BRCA mutation
  Region: US, EU, India
  Mechanism: Inhibits PARP enzymes that leads to accumulation of DNA damage in cancer cells with BRCA mutations
• Talzenna (talazoparib):
  Type: PARP Inhibitor
  Use: BRCA-mutated HER2-negative locally advanced or metastatic breast cancer
  Region: US, EU
  Mechanism: Blocks PARP activity and traps it on DNA, promoting tumor cell death in BRCA-mutated cancers
• Keytruda (pembrolizumab):
  Type: Immunotherapy (PD-1 Checkpoint Inhibitor)
  Use: Triple-Negative Breast Cancer (TNBC) in early and metastatic stages (with chemo)
  Region: US, EU, India
  Mechanism: Blocks PD-1 receptor on T-cells, restoring immune response against tumor cells
• Orserdu (elacestrant):
  Type: Oral Selective Estrogen Receptor Degrader (SERD)
  Use: ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer
  Region: US
  Mechanism: Binds and degrades estrogen receptors, blocking estrogen-driven tumor growth
• Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf):
  Type: Fixed-dose Subcutaneous HER2-targeted Therapy
  Use: HER2-positive early and metastatic breast cancer
  Region: US, EU
  Mechanism: Combines two HER2-targeting antibodies and allows subcutaneous (SC) administration for convenience and efficacy
• Nerlynx (neratinib):
  Type: Oral HER2 Tyrosine Kinase Inhibitor
  Use: Extended adjuvant therapy for HER2-positive early-stage breast cancer
  Region: US, EU
  Mechanism: Irreversibly inhibits HER1, HER2, and HER4, blocking growth signals in HER2-positive tumors
• Tukysa (tucatinib):
  Type: HER2 Tyrosine Kinase Inhibitor
  Use: HER2-positive metastatic breast cancer, including brain metastases
  Region: US, EU
  Mechanism: Selectively inhibits HER2 kinase activity while minimizing off-target toxicity, effective in CNS metastases
• Margenza (margetuximab):
  Type: Monoclonal Antibody
  Use: HER2-positive metastatic breast cancer after progression on anti-HER2 therapy
  Region: US
  Mechanism: Binds HER2 with enhanced Fc region affinity, promoting antibody-dependent cellular cytotoxicity
• Halaven (eribulin)
  Type: Microtubule Inhibitor (Chemotherapy)
  Use: Metastatic breast cancer after anthracycline and taxane therapy
  Region: US, EU, India
  Mechanism: Inhibits microtubule dynamics, leading to mitotic blockage and apoptosis
• Xeloda (capecitabine):
  Type: Oral Chemotherapy (Antimetabolite)
  Use: Metastatic breast cancer, especially HER2-negative, post-anthracycline/taxane
  Region: US, EU, India
  Mechanism: Converts to 5-FU in tumor tissue, interfering with DNA synthesis and function
• Afinitor (everolimus)
  Type: mTOR Inhibitor
  Use: HR+/HER2- advanced breast cancer with exemestane
  Region: US, EU, India
  Mechanism: Blocks mTOR pathway to block the growth of cancer cells, proliferation, and angiogenesis
• Zoladex (goserelin)
  Type: LHRH Agonist (Hormonal Therapy)
  Use: Hormone-sensitive premenopausal breast cancer (early and advanced)
  Region: Global
  Mechanism: Suppresses ovarian hormone production, lowering estrogen to slow hormone-receptor-positive cancer.  
• Accessing New Breast Cancer Medicines in India and Other Countries:
• Many of these advanced therapies may not yet be available or approved in all countries. Patients can still access these life-saving treatments through Named Patient Programs (NPPs), which legally allow the import of approved medicines from other markets based on medical need.
• Indian Pharma Network (IPN) — India’s Largest Named Patient Supply Company — helps patients, doctors, and hospitals gain legal, timely, and safe access to these hard-to-reach medicines.
• Whether it’s Enhertu, Orserdu, Verzenio, Trodelvy, or Lynparza, IPN facilitates the import under proper compliance with CDSCO, DGFT, and global regulatory frameworks.
• Why Choose Indian Pharma Network?
• ✅ Biggest Indian Company in the Named Patient Supply Segment
• ✅ 30+ Successful Years in Pharma Access Solutions
• ✅ 10,000+ Patients Served Globally
• ✅ 15,00,000+ Product Lines Accessed
• ✅ 20+ Therapeutic Areas Covered, including oncology, rare diseases, and autoimmune disorders
• ✅ Regulatory Compliance with CDSCO, DGFT, and Global Norms
• ✅ Cold Chain & Specialty Medicine Handling Expertise
• ✅ Trusted sourcing from US FDA, EMA, MHRA, and WHO-GMP certified facilities
• If you or a loved one has been diagnosed with Breast cancer and your treatment requires immediate access to a newly approved medicine that is not yet approved where you live, Indian Pharma Network is here to help. Contact us to explore your Breast cancer treatment options today.
• disclaimer: This content is for informational purposes only. It is not, and should not be construed as, professional medical advice, diagnosis, or treatment. Always seek the advice of your physician before starting any new therapy.
•